Search clinical trials for: WR 279,396

Total 485 results

U.S. Army Medical Research and Development Command

Completed

A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

Old World Cutaneous Leishmaniasis

Tunisia
Assistance Publique - Hôpitaux de Paris
U.S. Army Medical Research and Development Command

Completed

WR 279,396 for the Treatment of Cutaneous Leishmaniasis (PAGELEC)

Cutaneous Leishmaniasis

France
U.S. Army Medical Research and Development Command
Institut Pasteur

Completed

Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application (SCAR)

Scar | Cutaneous Leishmaniasis

Tunisia
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Terminated

WR 279,396 Open Label Treatment Protocol in Tunisia

Cutaneous Leishmaniasis

Tunisia
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

Cutaneous Leishmaniasis

France, Tunisia
U.S. Army Medical Research and Development Command

Completed

Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

Cutaneous Leishmaniasis

Tunisia
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military...

Terminated

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis (WRNMMC)

Leishmaniasis, Cutaneous

United States
U.S. Army Medical Research and Development Command

Completed

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Cutaneous Leishmaniasis

Panama
U.S. Army Medical Research and Development Command

Completed

Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

Leishmaniasis, Cutaneous

Peru
U.S. Army Medical Research and Development Command

Completed

Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama

Leishmaniasis, Cutaneous

Panama
Chinese Medical Association

Unknown

Effect of Dissecting of The Inferior Pulmonary Ligament on Postoperative Pulmonary Reexpansion and Recurrence

Pneumothorax

China
Lawson Health Research Institute

Completed

Early Detection of Skin Cancer With Sensor Technology

Carcinoma, Basal Cell
Hospital de Clinicas de Porto Alegre

Completed

Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.

Dyslipidemias
Uludag University

Completed

The Effect of Mobilization on Gastric Emptying Time

Anesthesia | Fasting

Turkey
IlDong Pharmaceutical Co Ltd

Completed

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Healthy Volunteers

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Asthma

United States, India, Spain, Italy, Israel, Netherlands, Russian Federation, Lebanon, South Africa, Czechia, Greece, Serbia, Argentina, Mexico, Slovakia, Canada, Taiwan, Malaysia, Japan
U.S. Army Medical Research and Development Command
Walter Reed Army Medical Center

Terminated

Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

Cutaneous Leishmaniasis

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Medical Center

Completed

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis

United States
National Cancer Institute (NCI)

Active, not recruiting

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Unresectable Breast Carcinoma

United States
University of Kentucky

Completed

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

Sarcoma | Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Unspecified Childhood Solid Tumor, Protocol Specific

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Recurrent Glioblastoma | IDH Family Wildtype | Recurrent Anaplastic Astrocytoma

United States
M.D. Anderson Cancer Center
Incyte Corporation

Active, not recruiting

Itacitinib for the Prevention of Graft Versus Host Disease

Hematologic and Lymphocytic Disorder

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

Unilateral Retinoblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7

United States
Obstetrix Medical Group

Completed

Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) (17PinPROM)

Preterm Delivery

United States
University of Utah

Terminated

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Primary Myelofibrosis | Anemia | Thrombocytopenia | Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | IDH2 Gene Mutation | IDH1 Gene Mutation | Secondary Myelofibrosis | ASXL1 Gene Mutation | EZH2 Gene Mutation

United States
National Cancer Institute (NCI)

Completed

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7

United States
Fred Hutchinson Cancer Center

Recruiting

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Minimal Residual Disease | Hematopoietic Cell Transplantation Recipient | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation

Active, not recruiting

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer

Recurrent Childhood Liver Cancer | Childhood Hepatoblastoma | Stage I Childhood Liver Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Solid Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Childhood Acute Lymphoblastic Leukemia in Remission

United States, Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing... and other conditions

United States, Canada, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Hematopoietic and Lymphoid Cell Neoplasm | Hematologic and Lymphocytic Disorder | Allogeneic Stem Cell Transplant Recipient

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Recurrent Glioblastoma | Recurrent Gliosarcoma
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States
Thomas Jefferson University

Recruiting

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Metastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver | Stage IV Choroidal and Ciliary Body Melanoma AJCC V8

United States
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Srinivas Devarakonda

Terminated

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Fred Hutchinson Cancer Center
National Cord Blood Network

Recruiting

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Chronic...

United States

Search clinical trials for: WR 279,396

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations